IKS Health opens Coimbatore office

IMT News Desk
IMT News Desk
· 2 min read

The 1000-seat, state-of-the-art facility is designed to accommodate the rapid expansion of IKS Health’s operations for the US Healthcare market

IKS Health announced the inauguration of its new office in Coimbatore. The event signifies a notable milestone in the company’s continuous trajectory of growth and global expansion across India and the world.

The 1000-seat, state-of-the-art facility is designed to accommodate the rapid expansion of IKS Health’s operations for the US Healthcare market. This new office is slated to become a significant talent hub, generating employment for recent university graduates, as well as experienced professionals with backgrounds in medicine, pharmacy, technology, and engineering.

Nithya Balasubramanian, Whole-time Director and CFO, IKS Health, said, “Our second quarter performance for Fiscal Year 2026 demonstrates our commitment to consistent, profitable growth, evidenced by a 22 per cent year-over-year growth in revenue, and a 60 per cent rise in Profit After Tax (PAT). This sustained momentum is fundamentally driven by our talented workforce. The strategic expansion of our local talent base in Coimbatore is crucial, as it enhances our capacity for execution excellence and allows us to vigorously pursue our long-term objectives of enabling better, safer healthcare in the US market.”

Manisha Kadagathur, Chief Human Resources Officer, IKS Health, said, “The opening of our new Coimbatore office underscores our commitment to generating meaningful employment opportunities in a fast growth industry. Coimbatore represents a vital source of exceptional talent and quality educational institutions. We are enthusiastic about engaging with recent graduates and seasoned professionals to forge enduring, impactful careers with our organization. IKS Health is dedicated to investing in the future of healthcare and the growth of individuals who will contribute to its advancement.”

Read Next

India successfully validates the first indigenous HPV test for Cervical Cancer screening
News
June 13, 2026

India successfully validates the first indigenous HPV test for Cervical Cancer screening

India has achieved a significant milestone in cervical cancer prevention with the successful validation of the country’s first indigenous HPV DNA tests, which meet international standards for cervical cancer screening. Published in the International Journal of Cancer, a multicentre study involving leading Indian and international institutions found that Molbio Diagnostics Truenat HPV-HR Plus met the […]
Article by: IMT News Desk
Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk